Fredun Pharmaceuticals Limited has fixed July 16, 2026 as the record date to determine shareholder eligibility for a 2:1 bonus issue. The company will issue two fully paid-up equity shares of ₹10 each for every one existing fully paid-up equity share of ₹10 held. This decision follows shareholder approval obtained during the Annual General Meeting held on June 30, 2026.

The deemed date of allotment for the bonus equity shares will be the next working day following the record date (T+1), in accordance with SEBI Circular No. CIR/CFD/PoD/2024/122 dated September 16, 2024. The newly issued shares will rank pari passu with existing equity shares, entitling holders to the same dividend and corporate benefits.

Bonus Issue Details

The company has confirmed that arrangements have been made to adjust the conversion ratio for outstanding warrants. This ensures that warrant holders receive the same economic benefit as if the warrants had been converted into equity shares prior to the record date, complying with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Fredun Pharmaceuticals Limited concluded its 39th Annual General Meeting on June 30, 2026, approving a 7% dividend on equity shares for the financial year ended March 31, 2026. The meeting, held via video conferencing, also sanctioned the issuance of bonus equity shares and an increase in the company's authorised share capital. These decisions were taken as part of the statutory business conducted during the session, which commenced at 09:00 a.m. IST and concluded at 9:20 a.m. IST.

The board's proposal to declare a dividend was among the key resolutions passed by the shareholders. In addition to the dividend, the meeting approved the re-appointment of Dr. (Mrs.) D. N. Medhora, Whole Time Director, who retires by rotation. The shareholders also granted approval for transactions with related parties and the ratification of the remuneration of the Cost Auditor for the financial year ending March 31, 2027.

Key Resolutions Passed

The AGM covered 11 resolutions, ranging from financial approvals to structural changes. The following table details the resolutions and their classification:

Proceedings and Participation

The meeting was chaired by Dr. (Mrs.) Daulat Nariman Medhora, Chairperson and Joint Managing Director. Ms. Vaishnavi Sahu, Company Secretary and Compliance Officer, oversaw the proceedings. A representative of M/s. R.H. Nisar & Co., Statutory Auditors, and Ms. Kala Agarwal, Practicing Company Secretary appointed as Scrutinizer, were present.

Mr. Fredun Medhora, Managing Director and Chief Financial Officer, apprised the members of the company's performance and highlights for FY 2025-26. He addressed queries from registered speaker shareholders, including Mr. Manjit Singh and Mr. Anil S. Gabaria, regarding the company's operations. The remote e-voting facility was available from June 27 to June 29, 2026, with e-voting also conducted at the meeting via the NSDL platform.